|Title:||Metered dose inhaler for salmeterol|
|Abstract:||A metered dose inhaler having part or all of its internal metallic surfaces coated with one or more fluorocarbon polymers, in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising salmeterol, or a salt thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents and one or more excipients.|
|Inventor(s):||Ashurst; Ian C. (Ware, GB), Herman; Craig S. (Raleigh, NC), Li; Li (Scotch Plains, NJ), Riebe; Michael T. (Raleigh, NC)|
|Assignee:||Glaxo Wellcome Inc. (Research Triangle Park, NC) Glaxo Group Limited (Greenford, GB)|
Patent Claim Types:|
see list of patent claims
|Formulation; Compound; Delivery; Device; Use; Composition;|
Field: Not categorized
Back Citations: 131st percentile
Forward Citations: 14th percentile
|Patent Number||Expiration Date|
|6,143,277||November 07, 2012|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|African Regional IP Organization (ARIPO)||9701113||► subscribe|
|African Regional IP Organization (ARIPO)||979||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.